Hubei Guangji Pharmaceutical Co.,Ltd. sold nearly half its share of Hubei Jifeng Industry Co for RMB 60 million. If the stock transfer procedure can be completed by the end of the year, Guangji Pharma could finish this year with over RMB 20 million revenue after 2 years deficit. 

As a public listed company, Guangji Pharma has experienced deficit for 2 years. After stripping of the assets and receiving various government subsidies, Guangji Pharma is highly possible to be earning this year.